New insights and results from the RE-LY trial

被引：0
|
作者：
不详
机构：
来源：
CARDIOVASCULAR JOURNAL OF AFRICA | 2011年 / 22卷 / 05期
关键词：
ATRIAL-FIBRILLATION; DABIGATRAN; WARFARIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：284 / 286
页数：2
相关论文
共 50 条
  • [21] Review of the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial: Warfarin versus dabigatran
    Ingelmo C.
    Wazni O.
    Current Cardiology Reports, 2011, 13 (5) : 357 - 360
  • [22] Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial
    Douketis, James D.
    Healey, Jeff S.
    Brueckmann, Martina
    Fraessdorf, Mandy
    Spyropoulos, Alex C.
    Wallentin, Lars
    Oldgren, Jonas
    Reilly, Paul
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Yusuf, Salim
    Eikelboom, John W.
    THROMBOSIS RESEARCH, 2016, 139 : 77 - 81
  • [23] RE-LY: low risk of intracranial haemorrhage with dabigatran
    Reactions Weekly, 2012, 1402 (1) : 3 - 3
  • [24] Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial
    Bytzer, Peter
    Connolly, Stuart J.
    Yang, Sean
    Ezekowitz, Michael
    Formella, Stephan
    Reilly, Paul A.
    Aisenberg, James
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (03) : 246 - +
  • [25] Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial
    Essebag, Vidal
    Proietti, Riccardo
    Birnie, David H.
    Wang, Jia
    Douketis, James
    Coutu, Benoit
    Parkash, Ratika
    Lip, Gregory Y. H.
    Hohnloser, Stefan H.
    Moriarty, Andrew
    Oldgren, Jonas
    Connolly, Stuart J.
    Ezekowitz, Michael
    Healey, Jeff S.
    EUROPACE, 2017, 19 (10): : 1630 - 1636
  • [26] Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation Results From the RE-LY Trial
    Stam-Slob, Manon C.
    Connolly, Stuart J.
    van der Graaf, Yolanda
    van der Leeuw, Joep
    Dorresteijn, Jannick A. N.
    Eikelboom, John W.
    Peters, Ron J. G.
    Alings, Marco
    Visseren, Frank L. J.
    CIRCULATION, 2019, 139 (25) : 2846 - 2856
  • [27] Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
    Dans, Antonio L.
    Connolly, Stuart J.
    Wallentin, Lars
    Yang, Sean
    Nakamya, Juliet
    Brueckmann, Martina
    Ezekowitz, Michael
    Oldgren, Jonas
    Eikelboom, John W.
    Reilly, Paul A.
    Yusuf, Salim
    CIRCULATION, 2013, 127 (05) : 634 - 640
  • [28] Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY
    Caldeira, Daniel
    da Silva, Pedro Alves
    Pinto, Fausto J.
    STROKE, 2023, 54 (06) : 1656 - 1659
  • [29] Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial
    Biszewski, Matthew
    Nitzki-George, Diane
    Zhou, Ying
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (07) : 557 - 562
  • [30] Patient outcomes using the European label for dabigatran A post-hoc analysis from the RE-LY database
    Lip, Gregory Y. H.
    Clemens, Andreas
    Noack, Herbert
    Ferreira, Jorge
    Connolly, Stuart J.
    Yusuf, Salim
    THROMBOSIS AND HAEMOSTASIS, 2014, 111 (05) : 933 - 942
12345